09/14/2026 | Abracro | BRA1

https://www.bra1.com.br/geral/id-692144/casos_de_doencas_raras_mostram_urgencia_em_buscar_novos_tratamentos_para_o_cerebro 

The diagnosis of influencer Lito Souza with Creutzfeldt-Jakob disease draws attention to the need for clinical research. Experts explain how studies can help patients who currently have no cure, highlighting the role of science and Brazilian laws in this process.

The recent diagnosis of digital influencer and aviation expert Lito Souza has shed light on Creutzfeldt-Jakob disease (CJD). This condition is rare and affects the nervous system, causing progressive deterioration. Currently, there is no treatment capable of halting or reversing the disease's progression in the human body.

However, Lito's case serves as more than just an informational story; it underscores the crucial importance of clinical research in the quest for new ways to cure or treat rare diseases. These studies involve volunteers to ensure that medications and vaccines are safe and effective before being used by the general population.

• Creutzfeldt-Jakob disease is a rare, neurodegenerative condition with no current cure.
• Clinical research tests the safety of new medicines using volunteers.
• Rare diseases require international collaboration due to the low number of patients.
• Law No. 14.874/2024 modernizes regulations regarding research involving human subjects in Brazil.
• Patients should consult doctors to determine if they meet study criteria.

What is Creutzfeldt-Jakob disease?
CJD is characterized by the accumulation of abnormal proteins known as prions in the brain. These proteins gradually damage nerve cells. As the disease affects the body's control system, neurological symptoms emerge and become increasingly severe over time.

The lack of therapeutic options means that specialists focus on prevention and the development of new medical technologies. That is why public attention regarding cases like Lito Souza’s is so valuable to science.

How to participate in clinical trials
Fernando de Rezende Francisco, executive director of the Brazilian Association of Clinical Research Organizations (ABRACRO), explains that not every patient can join just any study. There are strict rules that must be followed to protect the participants' health.

To participate in an ongoing study, recruitment must still be open and spots available. The first step is to verify whether the patient meets the inclusion criteria and does not present any of the exclusion criteria defined in the protocol, the specialist explains.

This means that each project has a list of requirements. If your profile does not match what the study aims to analyze, participation is not possible. Furthermore, one must wait for the specific window of time when new participants are accepted into the project.

Challenges in fighting rare diseases
Working with rare diseases is more complex than treating common ones. Since few patients across an entire country suffer from the same specific conditions, scientists must join forces.

It is often necessary to share data and patients among research centers, healthcare institutions, and scientists from different states or even other countries. This collaborative network is essential to ensure a sufficient number of samples to draw reliable conclusions about a new treatment.

Safety guaranteed by laws and protocols
No clinical trial happens overnight. All trials must follow a detailed roadmap known as a protocol. This document defines how the study will be conducted from start to finish, ensuring that no steps are skipped.

Before anything begins, projects must be reviewed by ethics committees and regulatory agencies. In Brazil, Law No. 14.874/2024 introduced new, clearer regulations for research involving human subjects. This demonstrates the country's commitment to aligning with international quality standards in healthcare.

Where to find information and scientific hope
If you or someone you know is seeking experimental treatments, the advice is simple: speak with the attending physician. They can recommend research institutions or organizations that assist patients in finding relevant studies.

Clinical research is more than just a stage for testing a new drug; it is essential for developing safe and effective treatments grounded in the scientific process of research, development, and innovation. For patients with rare diseases who currently lack specific therapies, every scientific breakthrough can offer new hope, concludes Francisco.